Preparation of Anti-EGFR Monoclonal Antibody Immunoconjugate (EQ75-ADR) and It's Inhibitory Effect on Human Epidermoid Carcinoma
- VernacularTitle:表皮生长因子受体单抗导向药物(EQ75-ADR)的制备及对人表皮癌抑瘤作用的研究
- Author:
Ying HE
;
Shangquan ZHANG
;
Feng ZHAO
;
Zhenghua WU
;
Yaofa WANG
;
Yuanchang YAN
- Publication Type:Journal Article
- Keywords:
anti-tumor;
immunoconjugate;
epidermal growth factor receptor(EGFR)
- From:
Chinese Journal of Cancer Biotherapy
1995;0(02):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To prepare an immunoconjugate of anti-EGFR monoclonal antibody (ETS) and adriamycin(ADR) and to investigute it's inhibitory effect on human epidermoid carcinoma (A431) in vitro and in vivo and it's side effect on C57BL/ 6J mice.Methods:The immunoconjugate(ETS-ADR) was prepared with an improved glutaraldehyde conjugate method and the cytotoxicity effects of EQ75-ADR on A431 cells and Wish cells were measured by MTT assay. A431 tumor-bearing nude mice and C57BL/6J experimental model were established and were used for testing the inhibitory edicts of EQ75-ADR. The side effect of EQ75-ADR was compared with ADR. Results:The EQ75-ADR showed specific cytotoxicity on A431cells,the ytotoxicity of EQ75-ADR was 50-fold, 14-fold and 10-fold more efficient than that of EQ75, ADR and mixture of EQ75 and ADR (EQ75+ ADR) respectively.The effect of EQ75-ADR on with cells was 10-fold less efficient than that of ADR and EQ75+ADR. As compared with the cytoxicity effect of EQ75-ADR on Wish cells with A431 cells, it showed 300-fold less efficient.Similar cytotoxicity results were shown in 2 h treatment experimental group. The EQ75-ADR exhibited significant anti-tumor activity on tumor-bearing nude mice,and the inhibition late is 92.2% (P
